Biweekly CAPOX versus triweekly CAPOX in the adjuvant therapy of post-surgery CRC: A randomized controlled trial
PLOS One · 2025
DOI: 10.1371/journal.pone.0313472 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift PLOS One, 2025. Verfasst von Hangyu Zhang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, P. R. China. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Capecitabine, Oxaliplatin, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Zhejiang Province.
Abstract (Originalsprache)
Purpose
This study aims to compare the safety and efficiency of modified biweekly CAPOX and conventional triweekly CAPOX in high-risk stage II and stage III post-surgery colorectal (CRC) patients.
Methods
From July 25, 2018, to May 14, 2021, high-risk stage II and stage III post-surgery CRC patients were randomized in the control triweekly group (intravenous infusion of oxaliplatin 130 mg/m 2 on day 1 and oral capecitabine 1000 mg/m 2 , twice daily from day 1 to day 14) and the experimental biweekly group (intravenous infusion of oxaliplatin 85 mg/m 2 on day 1 and oral capecitabine 1000 mg/m 2 , twice daily from day 1 to day 10). The primary endpoint was the incidence rate of thrombocytopenia. The secondary endpoint was 3-year disease free survival (DFS) rate. The patients follow up was started on July 25, 2018, and finished on October 8, 2024.
Results
A total of 160 patients were 1:1 randomly assigned (80 patients to biweekly group and 80 patients to triweekly group). All grade thrombocytopenia occurred in 33% and 49% patients at biweekly and triweekly group, respectively ( P = 0.02). Neutropenia presented in 36% and 51% patients at biweekly and triweekly group, respectively ( P = 0.04). The second endpoint 3-year DFS was 85.1% in biweekly group and 80.4% in triweekly CAPOX group ( P = 0.51, HR = 0.78, [95%CI, 0.38–1.63]). The total rate of uncomplete therapy patient was 7.5% and 15% in biweekly and triweekly group, respectively ( P = 0.13).
Conclusion
Biweekly CAPOX presented significant less thrombocytopenia and neutropenia than triweekly CAPOX regimen. There was no difference in 3-year DFS between biweekly CAPOX and triweekly CAPOX. Clinical trial registration: ClinicalTials.gov (NCT03564912).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, P. R. China.
- Department of colorectal surgery, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, P. R. China.
ORCID-Profile: Hangyu Zhang
Förderung
- Natural Science Foundation of Zhejiang Province
Zitieren
APA
Zhang, H., Wang, D., Tong, Z., Xiang, T., Zhu, X., Liu, L., Zheng, Y., Zhao, P., Fang, W., & Chen, W. (2025). Biweekly CAPOX versus triweekly CAPOX in the adjuvant therapy of post-surgery CRC: A randomized controlled trial. PLOS One. https://doi.org/10.1371/journal.pone.0313472
Vancouver
Zhang H, Wang D, Tong Z, Xiang T, Zhu X, Liu L, et al. Biweekly CAPOX versus triweekly CAPOX in the adjuvant therapy of post-surgery CRC: A randomized controlled trial. PLOS One. 2025. doi:10.1371/journal.pone.0313472
BibTeX
@article{Zhang2025,
author = {Zhang, Hangyu and Wang, Danyang and Tong, Zhou and Xiang, Tao and Zhu, Xudong and Liu, Lulu and Zheng, Yi and Zhao, Peng and Fang, Weijia and Chen, Wenbin},
title = {Biweekly CAPOX versus triweekly CAPOX in the adjuvant therapy of post-surgery CRC: A randomized controlled trial},
journal = {PLOS One},
year = {2025},
doi = {10.1371/journal.pone.0313472}
}
EUVIMED